Abstract-The platelet glycoprotein IIb/IIIa (GP IIb/IIIa) plays a pivotal role in platelet aggregation. Recent data suggest that the Pl A2 polymorphism of GPIIIa may be associated with an increased risk for cardiovascular disease. However, it is unknown if there is any association between this polymorphism and platelet reactivity. We determined GP IIIa genotype and platelet reactivity phenotype data in 1422 subjects from the Framingham Offspring Study. Genotyping was performed using PCR-based restriction fragment length polymorphism analysis. Platelet aggregability was evaluated by the Born method. The threshold concentrations of epinephrine and ADP were determined. Allele frequencies of Pl A1 and Pl A2 were 0.84 and 0.16, respectively. The presence of 1 or 2 Pl A2 alleles was associated with increased platelet aggregability as indicated by incrementally lower threshold concentrations for epinephrine and ADP. For epinephrine, the mean concentrations were 0.9 mol/L (0.9 to 1.0) for homozygous Pl A1 , 0.7 mmol/L (0.7 to 0.9) for the heterozygous Pl A1 /Pl A2 , and 0.6 mol/L (0.4 to 1.0) for homozygous Pl A2 individuals, Pϭ0.009. The increase in aggregability induced by epinephrine remained highly significant (Pϭ0.007) after adjustment for covariates. For ADP-induced aggregation, the respective mean concentrations were 3.1 mol/L (3.0 to 3.2), 3.0 mol/L (2.9 to 3.2), and 2. Key Words: platelets Ⅲ genetics Ⅲ glycoprotein Ⅲ epinephrine M yocardial infarction results from the formation of a platelet-rich thrombus at the site of a ruptured coronary atherosclerotic plaque. 1,2 The platelet surface receptor glycoprotein IIb/IIIa (GP IIb/IIIa) plays a key role in the formation of such a thrombus by binding fibrinogen and von Willebrand factor. The importance of the GP IIb/IIIa receptor has been further supported by recent clinical trials in which GP IIb/IIIa antagonists have been shown to reduce restenosis rate after angioplasty 3 and also to reduce the morbidity and mortality associated with unstable angina, 4 high-risk coronary angioplasty, 5 and acute myocardial infarction. 6 Although the Pl A1 and Pl A2 variants of GP IIIa have long been recognized as alloantigens and most frequently implicated in syndromes of immune-mediated platelet destruction, until recently little attention has been paid to their role in coronary heart disease. Weiss and colleagues 7 first reported that patients with acute coronary syndromes were more likely than were controls to carry the Pl A2 allele. The risk associated with Pl A2 was especially high for those aged 60 years or younger at the time of infarction. Recently, Walter and colleagues 8 reported that patients with the Pl A2 allele had an increased risk of coronary stent thrombosis compared with Pl A1 homozygous individuals. However, the association between the Pl A2 allele and cardiovascular disease has not been a consistent finding. Although Carter et al 9 supported the early findings of Weiss, ] several other studies failed to detect the association, 10 -15 including a large prospective study from the Physicians' Health Study. 10 Importantly, the mechanism for the possibly increased risk has not been determined. We hypothesized that the Pl A2 allele might be associated with an increase in platelet aggregability and tested this hypothesis in the Framingham Offspring Study.
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Methods

Study Population
The study subjects were members of the Framingham Offspring Study, a long-term, prospective evaluation of risk factors for cardiovascular disease. The design and methodology of the Framingham Offspring Study have been described in detail elsewhere. 16 The participants were natural or adopted children of the original Framingham Heart Study subjects. For this study, we collected data from subjects that were consecutively examined between April 3, 1991 and June 29, 1995, during the fifth Offspring Study examination cycle.
Of the 3799 subjects who attended examination cycle 5, blood samples were collected from 3286 subjects for platelet aggregation analysis. For the present analysis, we excluded subjects who were not members of a sibship (nϭ1298) because linkage analysis was also performed. We also excluded subjects in whom platelet aggregation data would not be determinable because of treatment with anticoagulant or antiplatelet drugs (nϭ536). Finally, we excluded subjects in whom genotyping could not be successfully accomplished (nϭ30). A total of 1422 subjects fulfilled all inclusion criteria.
Determination of Platelet Aggregability
Blood samples were always obtained in the morning to avoid the circadian change of platelet aggregability. Blood was drawn in 3.8% sodium citrate solution (9:1). Platelet-rich plasma was separated by centrifugation for 10 minutes at 160g. Platelet aggregation was measured on a 4-channel aggregometer according to the method of Born. 17 The aggregation agents tested were epinephrine and ADP in varying concentrations (0.01 to 30 mol/L), and a fixed concentration of arachidonic acid (1.6 mol/L). The lowest concentrations of ADP and epinephrine required to produce a biphasic response with Ͼ50% aggregation (threshold concentration) were determined. A decreased threshold concentration indicates an increase in platelet aggregability. In addition, the presence or absence of an aggregation in response to arachidonic acid was determined.
Genotyping
To detect the substitution of cytosine for thymidine at position 1565 in exon 2 of the glycoprotein IIIa gene that is responsible for the Pl A2 polymorphism, we used a modified PCR-based restriction fragment length polymorphism (RFLP) analysis. 18 Genomic DNA was isolated from whole blood. Genomic DNA (10 to 20 ng in 5 mL volume) was incubated at 96°C for 3 minutes, followed by addition of master-mix (10 L) to yield a final reagent concentration of 333 nmol/L for sense and antisense primer, 167 nmol/L of each of dATP, dTTP, dCTP, and dGTP, 2.5 mmol/L magnesium chloride, 50 mmol/L potassium chloride, 10 mmol/L Tris-HCl (pH 8.4 at 25°C), 0.1%Triton X-100, 0.02 mmol/L cresol red, and 83 mmol/L sucrose, as well as 0.15 U of Taq polymerase. The sequences of the sense and antisense primers were 5Јtgggacttctctttgggctcctgacttac3Ј and 5Јccttcagcagattctccttcaggtcac3Ј, respectively. DNA was amplified by 39 cycles of denaturing at 96°C for 20 seconds, annealing at 56°C for 40 seconds, and extension at 72°C for 30 seconds.
Restriction buffer (10 L) was added to yield a final concentration of 10 mmol/L Tris-HCl, 5.5 mmol/L magnesium chloride, 12.5 mmol/L sodium chloride, 30 mmol/L potassium chloride, 0.4 mmol/L dithiothreitol, and 0.1% Triton X-100. The samples were incubated at 37°C with 4 U of restriction endonuclease MspI overnight. This step was then repeated for complete digestion. In the presence of the Pl A2 allele, but not the Pl A1 allele, the 82 base pair (bp) amplification product was cleaved into fragments of 39 bp and 43 bp.
MspI digested amplification product (8 L) was loaded onto 2% agarose gel slabs containing 40 mmol/L Tris acetate and 2 mmol/L EDTA. Samples were size-fractionated at 6 V/cm for 30 minutes. Bands were visualized after staining with ethidium bromide by 300 nm UV transillumination. PCR results were scored without knowledge of platelet aggregability results. When there was any ambiguity, genotyping was repeated. Ninety-eight percent of the subjects were successfully genotyped.
Statistical Analysis
Demographic and clinical characteristics were compared among genotype groups by one-way ANOVA or by 2 test. The 2 test was also used to compare the observed allele and genotype frequencies against Hardy-Weinberg equilibrium prediction. Data on epinephrine and ADP threshold concentrations were log-transformed and compared among genotype groups by one-way ANOVA 19 as well as the nonparametric Kruskall-Wallis test. Post hoc pairwise comparisons among genotypes were performed using Scheffe's adjustment. Multiple regression was used to adjust for age, sex, body mass index (BMI), diabetes, triglyceride, total cholesterol and HDL cholesterol, the presence of cardiovascular disease (CVD), menopausal status, and estrogen replacement status. 19, 20 Separate models for recessive, dominant, and additive genetic effects were evaluated with use of appropriate dummy variables. Generalized estimating equation algorithms were used to correct for intrafamily correlations. 21 Data on platelet aggregation were expressed as geometric meanϮ95% confidence interval. A value of PϽ0.05 was regarded as statistically significant.
Finally, a test of genetic linkage based on excess allele sharing for the quantitative traits (epinephrine and ADP threshold concentrations) with GP IIIa genotype was carried out, using SIBPAL version 2.7 of S.A.G.E. (1996) . 22, 23 This program provides an estimate of the proportion of alleles identically shared by descent at the GP IIIa locus using the sibpairs under study. Under this algorithm, linkage between marker and phenotype results in a negative value for the slope of the regression of the squared trait difference on the estimated proportion of alleles.
Results
Subject Characteristics (Table 1) There were no significant differences among individuals within each genotype group for age, sex, BMI, diabetes mellitus, smoking, CVD, hypertension, triglyceride level, total and HDL cholesterol levels, or alcohol consumption. The allele frequencies of Pl A1 and Pl A2 were 0.84 and 0.16, respectively, and are in accord with those predicted by the Hardy-Weinberg equilibrium (Pϭ0.44).
The genotype frequencies were similar between subjects excluded from the present analysis in whom genotyping was performed and those included in the present analysis. The frequencies of Pl A1 homozygous, heterozygous and Pl A2 homozygous were 72.9%, 24.3%, and 2.8% among subjects excluded, and 71.5%, 26.0%, and 2.5%, respectively, among subjects included in the present analysis (Pϭ0.74).
Pl
A Polymorphism and Platelet Aggregability: Association Analysis (Table 2) Epinephrine-Induced Platelet Aggregation 
ADP-Induced Platelet Aggregation
There was a trend toward the Pl A2 allele being associated with a decreased threshold concentration for ADP, which was directionally consistent with the results seen with epinephrine-induced aggregation. However, the differences observed were not statistically significant (ANOVA, Pϭ0.48; Kruskall-Wallis test, Pϭ0.23); after adjustment for covariates, Pϭ0.19 (ANOVA).
Pl
A Polymorphism and Platelet Aggregability: Linkage Analyses Result 
Contribution of Genetic and Traditional Risk Factors to Platelet Aggregation (Table 3)
In the model for epinephrine-induced aggregation, sex accounted for 2.7% of the variance (PϽ0.0001), triglyceride 1.1% (PϽ0.0001), GP IIIa genotype 0.7% (Pϭ0.007), and age 0.5% (Pϭ0.08). The remaining variables contributed Ͻ0.2% each.
In the model for ADP-induced aggregation, sex accounted for 3.1% of the variance (PϽ0.0001), age 0.9% (Pϭ0.003), triglyceride 0.8% (Pϭ0.0006), HDL-cholesterol 0.5% (Pϭ0.006), hormone replacement therapy 0.3% (Pϭ0.03), and GP IIIa genotype 0.2% (Pϭ0.21). The remaining variables contributed Ͻ0.2% each.
Discussion
In the Framingham Offspring Study, the presence of 1 or 2 Pl A2 alleles of the platelet GP IIIa receptor was associated with an incrementally lower platelet threshold concentration in response to epinephrine and a trend toward lower threshold concentration in response to ADP. The increase in aggregability induced by epinephrine remained highly significant after adjustment for covariates. For epinephrine-induced aggregation, GPIIIa genotype explained 0.7% of the variance, while age, sex, and triglyceride accounted for an additional 4.3% of the variance.
GP IIIa Polymorphism and CVD
The familial clustering of coronary heart disease and the presence of a higher concordance in mortality among monozygotic twins compared with dizygotic twins suggest an important pathogenic role for genetic factors. 24 Although a small proportion of coronary heart disease can be attributed to single gene defects (eg, familial hypercholesterolemia or homocystinuria), the nature of additional contributing genetic factors remains largely unknown. Because platelets play a central role in the pathogenesis of acute CVD, it is possible that inherited platelet variants may contribute to CVD risk. Knowledge of such variants and their phenotypic expression may lead to progress in coronary disease risk assessment and therapeutic intervention. Weiss and colleagues 7 showed that patients with acute coronary syndromes were more likely than were controls to carry the Pl A2 allele. In their study, the prevalence of the Pl A2 allele was 2.1 times higher in the patients than among the controls. These findings, coupled with an anecdotal report about the sudden death of a 28-year-old Olympic skater who had severe coronary artery disease and carried the Pl A2 allele, but no other traditional risk factors, resulted in the Pl A1 /Pl A2 dimorphism receiving widespread attention. 25 Further studies of this genetic marker are warranted because, although there has been some support for the findings of Weiss et al, 9, 26 results from several other groups found no association between the Pl A2 allele and CVD, including an analysis by Ridker et al of the Physicians' Health Study. 10 -15 
GP IIIa Polymorphism and Platelet Aggregability
Platelet GP IIb/IIIa is the most abundant platelet receptor, with an estimated 50 000 copies per cell. 27 It is present in the platelet membrane as a heterodimeric complex whose formation requires the presence of divalent cations. The receptor is highly polymorphic and has long been recognized as having alloantigens. 28 Pl A alloantigens have been most frequently considered for their role in syndromes of immune-mediated platelet destruction, such as post-transfusion purpura and neonatal alloimmune thrombocytopenic purpura. 28 Newman and colleagues 18 identified the molecular basis of this polymorphism. The Pl A1 -allotype carries a leucine at position 33 of glycoprotein IIIa whereas the Pl A2 -allotype has a proline at position 33, because of a thymidine to cytosine substitution at 1565 in exon 2 of the glycoprotein IIIa gene.
The functional influence of the GP IIIa polymorphism on platelet reactivity is largely unknown. Using epinephrine as a platelet agonist, we found that the presence of the Pl A2 allele was associated with heightened platelet aggregability. Furthermore, the Pl A2 -associated increase in aggregability remained significant after adjustment for traditional risk factors that could influence platelet aggregability. The effect of the GP IIIa polymorphism on epinephrine-induced aggregation is in accordance with an additive model, with threshold concentration decreased by 19% per "dose" of Pl A2 allele (35% for Pl A2 homozygous) as compared with the Pl A1 homozygote. Using multiple regression analysis, we found that the polymorphism explained a small, but significant, percentage of variance of aggregability induced by epinephrine.
The platelet Pl A antigen system is not in the 2 putative RGD sequence binding regions of GP IIIa, which are located within residues 107 to 179 and 211 to 222 from the amino terminal, respectively. 29, 30 However, according to Calvete, 31 the Leu33/Pro33 polymorphism is enclosed within a small 13-amino acid loop formed by the pairing of Cys26 with Cys38. In addition, a long-range disulfide bond linking Cys5 and Cys435 has been identified which could bring the amino-terminal region of IIIa, including the small loop that contains the Pl A polymorphic residue, into immediate proximity with the binding regions of IIIa. 29, 30 Because of proline's unique structure, proline substitutions are well recognized for their propensity to induce conformational changes. Such changes can create alloantigenic determinants recognizable by T cells and B cells and induce the production of antibody. 32 The conformational changes could also influence activation of the GP IIb/IIIa receptor and alter platelet aggregability. Equally possible, the Pl A polymorphism may be in linkage disequilibrium with other as yet undefined molecular variants of the gene that influence platelet reactivity.
Goldschmidt-Clermont and colleagues 33 quantitated fibrinogen binding to platelets of different allotypes. The investigators found that platelets with the Pl A2 allele bound significantly less fibrinogen than did platelets that were homozygous for Pl A1 . Differences in methodology used to *In the epinephrine-induced aggregation, the remaining variables, including age, CVD, BMI, diabetes, total and HDL cholesterol, menopausal status, and HRT were not significantly associated with platelet aggregability. †In the ADP-induced platelet aggregation, CVD, BMI, diabetes, total cholesterol levels, and menopausal status, were not significantly associated with platelet aggregability. ‡HRT indicates hormone replacement therapy.
evaluate platelet reactivity in the study make it difficult to compare with our data. Additional larger and more comprehensive investigations will be required to resolve the issue. In a recent study, Cooke et al 34 found that platelets with the Pl A2 allele were more sensitive to aspirin inhibition.
Finally, we studied the relationship between the Pl A polymorphism and an intermediate phenotype (ie, platelet aggregability), rather than coronary heart disease. Although it has not been demonstrated that epinephrine-induced platelet aggregation is an independent risk factor for coronary heart disease, there is considerable evidence linking platelet reactivity to CVD. [35] [36] [37] In the Framingham Heart Study, we will prospectively follow the population to determine whether epinephrine-induced platelet aggregability and the Pl A2 allele are risk factors for CVD.
Limitations of the study
First, our analysis was based on a single measurement of platelet aggregation. However, any random variation or misclassification would introduce bias that favors the null hypothesis and an underestimation of the genetic contribution to platelet aggregability. Additional measures of platelet function should be evaluated in future studies. Second, our analysis was based on the subset of Framingham subjects in whom both genotype and phenotype data were available. However, the genotype distribution was similar between subjects excluded from analysis and those included in the present analysis. Third, a dimorphic marker was used for linkage analysis. Although not statistically significant, the results of the linkage analysis are consistent with the findings for the association studies as indicated by the negative slope of the regression line. The failure to reach statistical significance is not surprising. Because of the limited informativity of the marker used (heterozygosity indexϭ0.27), and the limited extent to which parental (ie, identity by descent) information was available, we had limited power to detect a statistically significant linkage. In future studies, a more informative marker should be used for linkage analysis. Finally, we used platelet aggregability to evaluate the relation between the Pl A polymorphism and platelet function. Although platelet aggregation studies in platelet-rich plasma can assess the effect of platelet inhibitors such as aspirin, the in vivo correlates and clinical significance of changes in platelet aggregation need to be defined more fully.
Implications of the Study
We found that the Pl A2 allele was associated with increased platelet aggregability in the Framingham Offspring Study. Our results support the hypothesis that Pl A2 might be a genetic risk factor for CVD, [7] [8] [9] and provide a mechanism for the link. Because epinephrine-induced aggregation was increased with the Pl A2 allele, and because increased aggregability has been described after assumption of an upright posture 35 and strenuous exercise, 38 it would be of interest to determine whether subjects with different Pl A alleles react differently to strenuous exercise. Such a study may not only provide additional insights into the mechanism by which strenuous exercise triggers the onset of cardiovascular events, 39 but may also help in selecting individuals for appropriate preventive therapy. In addition, further prospective studies are needed to test if this genetic marker is an independent risk factor for CVD.
If individuals with the Pl A2 allele have a higher incidence of CVD, they may benefit from more aggressive measures for prevention and treatment of CVD, including therapy with antiplatelet agents such as GP IIb/IIIa receptor antagonists.
